{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T12:36:24Z","timestamp":1788957384219,"version":"build-2803163510"},"reference-count":36,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T00:00:00Z","timestamp":1627862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/bmj.com\/coronavirus\/usage"}],"funder":[{"DOI":"10.13039\/501100004431","name":"Fondation de France","doi-asserted-by":"publisher","award":["00113315"],"award-info":[{"award-number":["00113315"]}],"id":[{"id":"10.13039\/501100004431","id-type":"DOI","asserted-by":"publisher"}]},{"name":"F\u00e9d\u00e9ration internationale de l'automobile","award":["no Grant \/ Award Number"],"award-info":[{"award-number":["no Grant \/ Award Number"]}]},{"name":"Donators from Paris Brain Institute - ICM","award":["no Grant \/ Award Number"],"award-info":[{"award-number":["no Grant \/ Award Number"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>SARS-CoV-2 seroconversion rate after COVID-19 may be influenced by disease-modifying therapies (DMTs) in patients with multiple sclerosis (MS) or neuromyelitis optica spectrum disorders (NMO-SD).<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To investigate the seroprevalence and the quantity of SARS-CoV-2 antibodies in a cohort of patients with MS or NMO-SD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Blood samples were collected in patients diagnosed with COVID-19 between 19 February 2020 and 26 February 2021. SARS-CoV-2 antibody positivity rates and Ig levels (anti-S IgG titre, anti-S IgA index, anti-N IgG index) were compared between DMTs groups. Multivariate logistic and linear regression models were used to estimate the influence of DMTs and other confounding variables on SARS-CoV-2 serological outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>119 patients (115\u2009MS, 4 NMO, mean age: 43.0 years) were analysed. Overall, seroconversion rate was 80.6% within 5.0 (SD 3.4) months after infection. 20\/21 (95.2%) patients without DMT and 66\/77 (85.7%) patients on DMTs other than anti-CD20 had at least one SARS-CoV-2 Ig positivity, while this rate decreased to only 10\/21 (47.6%) for patients on anti-CD20 (p&lt;0.001). Being on anti-CD20 was associated with a decreased odd of positive serology (OR, 0.07 (95% CI 0.01 to 0.69), p=0.02) independently from time to COVID-19, total IgG level, age, sex and COVID-19 severity. Time between last anti-CD20 infusion and COVID-19 was longer (mean (SD), 3.7 (2.0) months) in seropositive patients compared with seronegative patients (mean (SD), 1.9 (1.5) months, p=0.04).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>SARS-CoV-2 antibody response was decreased in patients with MS or NMO-SD treated with anti-CD20 therapies. Monitoring long-term risk of reinfection and specific vaccination strategies in this population may be warranted.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration number<\/jats:title><jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04568707\">NCT04568707<\/jats:ext-link>.<\/jats:p><\/jats:sec>","DOI":"10.1136\/jnnp-2021-326904","type":"journal-article","created":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T17:35:36Z","timestamp":1627925736000},"page":"24-31","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":52,"title":["Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders"],"prefix":"10.1136","volume":"93","clinical-trial-number":[{"clinical-trial-number":"nct04568707","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04355611","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4987-1531","authenticated-orcid":false,"given":"C\u00e9line","family":"Louapre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michella","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7699-0328","authenticated-orcid":false,"given":"Elisabeth","family":"Maillart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basma","family":"Abdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4074-6125","authenticated-orcid":false,"given":"Caroline","family":"Papeix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Stankoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Laure","family":"Dubessy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Bensa-Koscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Cr\u00e9ange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zina","family":"Chamekh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Lubetzki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Genevi\u00e8ve","family":"Marcelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Christophe","family":"Corvol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Pourcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,8,2]]},"reference":[{"key":"2024021904150816000_93.1.24.1","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/jamaneurol.2020.2581","article-title":"Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis","volume":"77","author":"Louapre","year":"2020","journal-title":"JAMA Neurol"},{"key":"2024021904150816000_93.1.24.2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26028"},{"key":"2024021904150816000_93.1.24.3","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2021.0688","article-title":"Outcomes and risk factors associated with SARS-CoV-2 infection in a North American registry of patients with multiple sclerosis","volume":"78","author":"Salter","year":"2021","journal-title":"JAMA Neurol"},{"key":"2024021904150816000_93.1.24.4","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2016.21"},{"key":"2024021904150816000_93.1.24.5","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1111\/ene.14790","article-title":"Untreated patients with multiple sclerosis: a study of French expert centers","volume":"28","author":"Moisset","year":"2021","journal-title":"Eur J Neurol"},{"key":"2024021904150816000_93.1.24.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.01.007"},{"key":"2024021904150816000_93.1.24.7","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.cell.2020.09.038","article-title":"Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity","volume":"183","author":"Rydyznski Moderbacher","year":"2020","journal-title":"Cell"},{"key":"2024021904150816000_93.1.24.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00575-4"},{"key":"2024021904150816000_93.1.24.9","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.4302","article-title":"Association of age with SARS-CoV-2 antibody response","volume":"4","author":"Yang","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2024021904150816000_93.1.24.10","article-title":"SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19","volume":"12","author":"Wu","year":"2021","journal-title":"Nat Commun"},{"key":"2024021904150816000_93.1.24.11","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.1016\/S2666-5247(21)00025-2","article-title":"Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study","volume":"2","author":"Chia","year":"2021","journal-title":"Lancet Microbe"},{"key":"2024021904150816000_93.1.24.12","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102482","article-title":"Beyond COVID-19: do MS\/NMO-SD patients treated with anti-CD20 therapies develop SARS-CoV2 antibodies?","volume":"46","author":"Maillart","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"2024021904150816000_93.1.24.13","article-title":"COVID-19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response","author":"Zabalza","year":"2020","journal-title":"Eur J Neurol"},{"key":"2024021904150816000_93.1.24.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001282"},{"key":"2024021904150816000_93.1.24.15","article-title":"Longitudinal assessment of anti-SARS-CoV-2 immune responses for six months based on the clinical severity of COVID-19","author":"Noh","year":"2021","journal-title":"J Infect Dis"},{"key":"2024021904150816000_93.1.24.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917246"},{"key":"2024021904150816000_93.1.24.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1601277"},{"key":"2024021904150816000_93.1.24.18","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamaneurol.2013.3071","article-title":"A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder","volume":"70","author":"Kim","year":"2013","journal-title":"JAMA Neurol"},{"key":"2024021904150816000_93.1.24.19","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00415-018-8771-5","article-title":"Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study","volume":"265","author":"Cabre","year":"2018","journal-title":"J Neurol"},{"key":"2024021904150816000_93.1.24.20","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-020-00092-2"},{"key":"2024021904150816000_93.1.24.21","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21363"},{"key":"2024021904150816000_93.1.24.22","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000825"},{"key":"2024021904150816000_93.1.24.23","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","article-title":"Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies","volume":"77","author":"Luna","year":"2020","journal-title":"JAMA Neurol"},{"key":"2024021904150816000_93.1.24.24","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000977"},{"key":"2024021904150816000_93.1.24.25","doi-asserted-by":"crossref","first-page":"e1999","DOI":"10.1212\/WNL.0000000000010380","article-title":"Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: the VELOCE study","volume":"95","author":"Bar-Or","year":"2020","journal-title":"Neurology"},{"key":"2024021904150816000_93.1.24.26","doi-asserted-by":"publisher","DOI":"10.1002\/art.25033"},{"key":"2024021904150816000_93.1.24.27","doi-asserted-by":"publisher","DOI":"10.1002\/art.25034"},{"key":"2024021904150816000_93.1.24.28","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.kint.2020.12.001","article-title":"Decline and loss of anti-SARS-CoV-2 antibodies in kidney transplant recipients in\u00a0the 6 months following SARS-CoV-2 infection","volume":"99","author":"Chavarot","year":"2021","journal-title":"Kidney Int"},{"key":"2024021904150816000_93.1.24.29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0245424","article-title":"Influence of obesity on serum levels of SARS-CoV-2-specific antibodies in COVID-19 patients","volume":"16","author":"Frasca","year":"2021","journal-title":"PLoS One"},{"key":"2024021904150816000_93.1.24.30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2026116G"},{"key":"2024021904150816000_93.1.24.31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2025179pmid:32706954"},{"key":"2024021904150816000_93.1.24.32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21111-9"},{"key":"2024021904150816000_93.1.24.33","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(20)30634-4"},{"key":"2024021904150816000_93.1.24.34","doi-asserted-by":"crossref","DOI":"10.1007\/s10096-021-04232-3","article-title":"Performance of 30 commercial SARS-CoV-2 serology assays in testing symptomatic COVID-19 patients","author":"Vauloup-Fellous","year":"2021","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2024021904150816000_93.1.24.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.08.017"},{"key":"2024021904150816000_93.1.24.36","unstructured":"Kister I , Krogsgaard M , Mulligan MJ . Preliminary results of ongoing, prospective study of antibody and T\u2010cell responses to SARS\u2010CoV\u20102 in patients with MS on ocrelizumab or other disease\u2010modifying therapies. 73rd Congress of the American Academy of Neurology (AAN) Virtual 2021. 17\u201322 April 2021;Presentation Number P15.014."}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2021-326904","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T12:16:17Z","timestamp":1708344977000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2021-326904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,2]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12,14]]},"published-print":{"date-parts":[[2022,1]]}},"alternative-id":["10.1136\/jnnp-2021-326904"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2021-326904","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,2]]}}}